ACAD
34.36
+0.04
+0.12%
AEMD
5.56
+0.11
+2.02%
APRI
0.362
-0.021
-5.4308%
ARNA
1.68
0.00
0.00%
ATEC
0.31
-0.03
-8.82%
CNAT
1.93
0.00
0.00%
CRXM
0.171
0.00
0.00%
CYTX
2.19
0.00
0.00%
DXCM
92.09
+1.53
+1.69%
GNMK
8.8
+0.13
+1.50%
HALO
10.1
-0.2
-1.94%
ILMN
172.79
-0.96
-0.55%
INNV
0.45
-0.01
-2.17%
INO
9.14
+0.08
+0.88%
ISCO
2
+0.03
+1.52%
ISIS
57.56
0.00
0.00%
LGND
108.07
+1.25
+1.17%
LPTN
2.68
-0.5
-15.72%
MBVX
5.35
+0.24
+4.70%
MEIP
2.05
+0.01
+0.49%
MNOV
6.55
+0.08
+1.24%
MRTX
5.46
+0.04
+0.74%
MSTX
0.415
+0.001
+0.266%
NBIX
51.5
-0.03
-0.05%
NUVA
64.1
+0.59
+0.93%
ONCS
1.797
-0.033
-1.8087%
ONVO
4.01
-0.04
-0.99%
OREX
4.34
-0.07
-1.59%
OTIC
17.26
-0.05
-0.29%
QDEL
21.55
+0.24
+1.13%
RCPT
231.96
0.00
0.00%
RGLS
3.44
-0.03
-0.86%
RMD
67.32
-2.46
-3.53%
SPHS
3.89
-1.93
-33.16%
SRNE
6.96
+0.01
+0.14%
TROV
5.21
-0.2
-3.70%
VICL
4.1
-0.06
-1.44%
VOLC
18
0.00
0.00%
ZGNX
9.56
-0.04
-0.42%
ACAD
34.36
+0.04
+0.12%
AEMD
5.56
+0.11
+2.02%
APRI
0.362
-0.021
-5.4308%
ARNA
1.68
0.00
0.00%
ATEC
0.31
-0.03
-8.82%
CNAT
1.93
0.00
0.00%
CRXM
0.171
0.00
0.00%
CYTX
2.19
0.00
0.00%
DXCM
92.09
+1.53
+1.69%
GNMK
8.8
+0.13
+1.50%
HALO
10.1
-0.2
-1.94%
ILMN
172.79
-0.96
-0.55%
INNV
0.45
-0.01
-2.17%
INO
9.14
+0.08
+0.88%
ISCO
2
+0.03
+1.52%
ISIS
57.56
0.00
0.00%
LGND
108.07
+1.25
+1.17%
LPTN
2.68
-0.5
-15.72%
MBVX
5.35
+0.24
+4.70%
MEIP
2.05
+0.01
+0.49%
MNOV
6.55
+0.08
+1.24%
MRTX
5.46
+0.04
+0.74%
MSTX
0.415
+0.001
+0.266%
NBIX
51.5
-0.03
-0.05%
NUVA
64.1
+0.59
+0.93%
ONCS
1.797
-0.033
-1.8087%
ONVO
4.01
-0.04
-0.99%
OREX
4.34
-0.07
-1.59%
OTIC
17.26
-0.05
-0.29%
QDEL
21.55
+0.24
+1.13%
RCPT
231.96
0.00
0.00%
RGLS
3.44
-0.03
-0.86%
RMD
67.32
-2.46
-3.53%
SPHS
3.89
-1.93
-33.16%
SRNE
6.96
+0.01
+0.14%
TROV
5.21
-0.2
-3.70%
VICL
4.1
-0.06
-1.44%
VOLC
18
0.00
0.00%
ZGNX
9.56
-0.04
-0.42%
Home » Archive by Category

Syndication

Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants

August 22, 2016 – 1:01 pm

SAN DIEGO and VANCOUVER, British Columbia, Aug. 22, 2016 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (“Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that it intends to offer and sell, subject to market and other conditions, its common shares and warrants to purchase additional common shares in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Piper Jaffray & Co. is acting as sole book-running manager for the offering. 

The securities described above are being offered by Sophiris pursuant to an effective shelf registration statement filed by Sophiris with the Securities and Exchange Commission (“SEC”) that became effective on October 3, 2014. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from Piper Jaffray & Co., by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin has successfully completed a Phase 3 clinical study for the treatment of the symptoms of benign prostatic hyperplasia (BPH), and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin has also successfully completed a Phase 2a study for the treatment of clinically significant, localized low to intermediate risk prostate cancer prior to radical therapy. For more information, please visit www.sophirisbio.com.

Safe Harbor / Forward-Looking Statements

Statements in this press release that are not strictly historical in nature, including statements related to the proposed offering of securities by Sophiris, are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities. For a discussion of these and other factors, please refer to Sophiris’ annual report on Form 10‑K for the year ended December 31, 2015 as well as Sophiris’ subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Sophiris undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Company Contact:
Peter Slover
Chief Financial Officer
(858) 777-1760

Corporate Communications and Investor Relations:

Jason Spark 

Canale Communications

Corporate Communications and IR

(619) 849-6005

jason@canalecomm.com

Michael Moore

NATIONAL Equicom

Investor Relations

(858) 886-7813

mmoore@national.ca

 

SOURCE Sophiris Bio Inc.

Kindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA

August 22, 2016 – 1:01 pm

SAN FRANCISCO, Aug. 22, 2016 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission of the Effectiveness Technical Section of the New Animal Drug Application for Mirataz™ (mirtazapine transdermal ointment) to the Food and Drug Administration (FDA) for the management of weight loss in cats. The Chemistry, Manufacturing, and Controls Technical Section was submitted in May 2016 and the Company plans to submit the Safety Technical Section in the third quarter of 2016.

The multicenter, randomized, double-blind, placebo-controlled pivotal field study enrolled 231 cats to assess the effectiveness of Mirataz for the management of weight loss in cats. The primary endpoint was percentage change in body weight from Day 1 to Week 2. At Week 2, the mean percent increase in body weight from Day 1 was 4.07% in the KIND-010 group (n=90), versus 0.29% in the placebo group (n=97) (p<0.0001). Based on a review of the safety data, the drug appears to be well tolerated.

“We are excited about the market potential for Mirataz and are pleased to bring this program one step closer to approval. Managing weight loss in cats is a serious unmet medical need, with an estimated 9 million cats in the U.S. suffering from inappetence. As a transdermal product, Mirataz is an attractive alternative for veterinarians and owners to administering a drug orally to cats. I want to thank the KindredBio team and our investigators for their hard work as we advance our plan to launch Mirataz,” stated Richard Chin, M.D., President and CEO of KindredBio.

Weight loss is one of the leading causes of veterinary visits among cat owners, and a veterinarian will see on average 7 cats per week with this condition. In many cases, significant weight loss can lead to liver failure and ultimately death. Currently, there are limited options for the management of weight loss in cats, none of which include an FDA-approved transdermal option. As a transdermal product, Mirataz is formulated using KindredBio’s Accusorb™ technology, which results in high and predictable absorption. About 80% of veterinarians surveyed have indicated their intent to use the product, based on the Company’s market research.

About Kindred Biosciences, Inc. 

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash. 

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements.  These risks include, but are not limited to, the following:  our limited operating history and expectations of losses for the foreseeable future; the absence of revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.  

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC.  As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release.   Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law. 

Contact

Russell Radefeld
KindredBio
Russell.radefeld@kindredbio.com 
(650) 701-7904

 

SOURCE Kindred Biosciences, Inc.

NGS Product Development Scientist (San Diego)

August 22, 2016 – 11:19 am

Seeking a PhD Scientist with Next Generation Sequencing and Product Development Experience!
This is a BENCH position.
Molecular Diagnostics experience required.
Some component of Product Development required.
Hands on NGS and DNA work.
Industry […

Quality Assurance (QA)/Quality Control (QC) Associate (SCIENCE)

August 22, 2016 – 11:09 am

Kelly Scientific is seeking Quality Assurance/Quality Control personnel. We have a number of open positions with our clients in San Diego. Seeking candidates with experience in Quality Assurance, or Quality Control with Document control. Experience w […

Full-Time Jobs to Protect Public Health- MGMT Needed< Avg. $450-650/wk (Hillcrest)

August 22, 2016 – 11:00 am

For more information call
show contact info
Keywords: grassroots, campaign, canvass, social change, activism, citizen outreach, environment, consumer, public interest, nonprofit.

Business Development Representative – Redbock – Encinitas, CA

August 22, 2016 – 10:52 am

Medical device, pharmaceutical, and biotechnology companies. To research and develop new business for Redbock through sales activities directed at decision…From Postings.com – Mon, 22 Aug 2016 17:52:01 GMT – View all Encinitas jobs

Lab Technician/ Research Assistant

August 22, 2016 – 10:44 am

Essential Duties and Responsibilities:
The Lab Assistant will support laboratory staff by maintaining the overall sanitation and organization of the laboratory, while assisting in other tasks as needed. The essential functions include, but are not l […

Eye Bank Technician (Kearny Mesa)

August 22, 2016 – 9:03 am

Are you a dedicated, ambitious, detail-conscious individual looking for a team-oriented work environment which supports learning and growth? Do you seek a rewarding position helping others, each and every day; a position you can be proud of?
If yes, […

Software Engineer (.Nert Developer) – Indus Software Solutions Inc. – San Diego, CA

August 22, 2016 – 8:38 am

Experience in biotech is a plus. Work as part of a scrum team to design, implement, and test instrument control software for genome sequencing instruments… $41 an hourFrom Indeed – Mon, 22 Aug 2016 15:38:37 GMT – View all San Diego jobs

Software Engineer (.Net Developer) – Indus Software Solutions Inc. – San Diego, CA

August 22, 2016 – 8:38 am

Experience in biotech is a plus. Work as part of a scrum team to design, implement, and test instrument control software for genome sequencing instruments… $41 an hourFrom Indeed – Mon, 22 Aug 2016 15:38:37 GMT – View all San Diego jobs